Some 900 patients selected by rigorous criteria will be enrolled at 10 treatment centers widely dispersed around the country when the second phase of the national double-blind cooperative study to evaluate chenodeoxycholic acid as a dissolving agent for cholesterol gallstones gets under way next year. The questions being asked by the study and the structure established to assure definitive answers are detailed.